Vistagen Therapeutics (VTGN) Non-Current Deffered Revenue (2013 - 2025)
Vistagen Therapeutics (VTGN) posted Non-Current Deffered Revenue of $176000.0 for Q4 2025, down 47.62% sequentially from $336000.0 in Q3 2025, and down 61.23% YoY from $454000.0 in Q4 2024.
Vistagen Therapeutics (VTGN) Non-Current Deffered Revenue (2013 - 2025) Analysis & Trends
Vistagen Therapeutics has reported Non-Current Deffered Revenue for 12 years, with the latest figure at $176000.0 in Q4 2025.
- Quarterly Non-Current Deffered Revenue fell 61.23% year-over-year to $176000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $176000.0 (down 61.23% YoY) and the FY2025 annual result came in at $391000.0, down 85.38% from the prior year.
- Non-Current Deffered Revenue slipped to $176000.0 in Q4 2025 per VTGN's latest filing, from $336000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $2.7 million in Q1 2024 and troughed at $176000.0 in Q4 2025.
- A 5-year average of $1.5 million and a median of $1.7 million in 2021 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue soared 75.47% in 2022, then sank 85.38% in 2025.
- Over 5 years, Non-Current Deffered Revenue stood at $1.4 million in 2021, then soared by 75.47% to $2.5 million in 2022, then dropped by 23.79% to $1.9 million in 2023, then plunged by 76.1% to $454000.0 in 2024, then sank by 61.23% to $176000.0 in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $176000.0, $336000.0, and $221000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 176,000.00 |
| Sep 30, 2025 | 336,000.00 |
| Jun 30, 2025 | 221,000.00 |
| Mar 31, 2025 | 391,000.00 |
| Dec 31, 2024 | 454,000.00 |
| Sep 30, 2024 | 730,000.00 |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 2.67 Mn |
| Dec 31, 2023 | 1.90 Mn |
| Sep 30, 2023 | 1.78 Mn |
| Jun 30, 2023 | 2.14 Mn |
| Mar 31, 2023 | 2.32 Mn |
| Dec 31, 2022 | 2.49 Mn |
| Sep 30, 2022 | 2.67 Mn |
| Jun 30, 2022 | 1.25 Mn |
| Mar 31, 2022 | 1.56 Mn |
| Dec 31, 2021 | 1.42 Mn |
| Sep 30, 2021 | 1.78 Mn |
| Jun 30, 2021 | 2.14 Mn |
| Mar 31, 2021 | 2.49 Mn |